The estimated Net Worth of Michael Terrence Gibbs is at least $12.7 Thousand dollars as of 24 February 2024. Mr. Gibbs owns over 29 units of T2 Biosystems Inc stock worth over $311 and over the last 9 years he sold TTOO stock worth over $12,428. In addition, he makes $0 as Vice President and General Counsel at T2 Biosystems Inc.
Michael has made over 17 trades of the T2 Biosystems Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 29 units of TTOO stock worth $67 on 24 February 2024.
The largest trade he's ever made was exercising 145,719 units of T2 Biosystems Inc stock on 24 February 2022 worth over $335,154. On average, Michael trades about 9,069 units every 85 days since 2016. As of 24 February 2024 he still owns at least 135 units of T2 Biosystems Inc stock.
You can see the complete history of Mr. Gibbs stock trades at the bottom of the page.
Michael Gibbs Esq serves as Vice President, General Counsel of the Company. Michael Gibbs, Esq. has served as our Vice President and General Counsel since January 2016. Mr. Gibbs joined our company in December 2014 as Senior Corporate Counsel. From 2011 until he joined our company, Mr. Gibbs was General Counsel for Keystone Dental, Inc., a medical device company focused on dental implants and biomaterials. From 2003 to 2011, Mr. Gibbs was a corporate attorney with the law firm Bingham McCutchen LLP (now Morgan Lewis & Bockius). Prior to joining Bingham McCutchen LLP, he was an officer in the United States Marine Corps, departing with the rank of Major. Mr. Gibbs received his J.D. from Boston College Law School and his B.S. in Political Science from Syracuse University.
Michael Gibbs is 49, he's been the Vice President and General Counsel of T2 Biosystems Inc since 2016. There are 14 older and 4 younger executives at T2 Biosystems Inc. The oldest executive at T2 Biosystems Inc is John Cumming, 74, who is the Lead Independent Director.
Michael's mailing address filed with the SEC is 101, Hartwell Avenue, Lexington, Middlesex County, Massachusetts, 02421, United States.
Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ..., and Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
T2 Biosystems Inc executives and other stock owners filed with the SEC include: